Company Overview and News
The decision of the Supreme Court (SC) to junk the government’s ill-gotten wealth case against late President Ferdinand Marcos and his cronies “opened up deep wounds” in the Philippines’ psyche, Akbayan Rep. Tom Villarin said on Tuesday.
The Supreme Court (SC) has nixed the government’s bid to claim P51-billion from the estate of the late Ferdinand Marcos and his cronies for damages over alleged ill-gotten wealth.
Sy Lian Teng inside the landmark Bergs Department Store —photo from the collection of Robert and Lorraine SYLIANTENG
PNB’s Human Resource Head Bong Austero recently arranged a Robotics workshop attended by PNB’s Board and Senior Management Team. Yes, you read it correctly: robotics! We assembled our own robots and programmed them to move in a specific way. It was challenging at first as we familiarized ourselves with programming language, but once we moved to the testing stage when we checked if our robots were moving in the way we wanted them to, it became fun.
BALANGA CITY — The Sandiganbayan has cleared former Samal town Mayor Rolando Tigas and Bataan Provincial Board Member Rafael Guinto of graft charges over a purchase of land for a public market in 2005.
THE GROWTH of banking stocks slowed during the quarter as market volatility sent investors into profit-taking mode despite the sector’s good earnings reports. For this quarter, however, most analysts interviewed have signaled a “buy” on the sector amid expectations of better earnings in the months ahead.
EW UBNC PSKXF CHIB BDOUY RZLLY PBB RCB SECB CKGOY AUB BDOUF BDO SYBJF PNB PHSXY PSE COL PTC
After the fall of Mighty Corp. as a result of the government’s crackdown on illicit cigarette trading last year, some remnants of “underground” cigarette business continue to operate locally—at a smaller scale than before but still enough to cause concern, the chief of conglomerate LT Group Inc. (LTG) said.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...